- Previous Close
0.2900 - Open
0.2910 - Bid --
- Ask --
- Day's Range
0.2890 - 0.3060 - 52 Week Range
0.2200 - 0.5200 - Volume
60,957 - Avg. Volume
57,190 - Market Cap (intraday)
15.272M - Beta (5Y Monthly) -0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0800 - Earnings Date Mar 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. The company offers Myrian Imaging Layer, a multimodal visualization software platform suite for health industrials; Myrian Studio, a solution for the development of medical imaging applications for innovators, industrial clients, spin-offs, and research labs; and Myrian technologies to develop biomarkers and artificial intelligence solutions. It also provides Myrian Clinical Apps, a portfolio of clinical applications for advanced post-processing, which include Myrian XP-Breast; Myrian XP-Prostate; Myrian XP-Liver; Myrian XP-Mammo; Myrian XP-Lung; Myrian XP-Colon; Myrian XL-Onco, a lesion tracking solutions; Myrian XP-Vessel; Myrian XP-Cardiac; solution for pathology or organ; and various tools for the analysis of MRI, CT, conventional, radiology, and nuclear imaging exams. The company was incorporated in 2004 and is headquartered in Montpellier, France.
www.intrasense.fr74
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ALINS.PA
View MorePerformance Overview: ALINS.PA
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALINS.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALINS.PA
View MoreValuation Measures
Market Cap
14.85M
Enterprise Value
14.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.26
Price/Book (mrq)
2.81
Enterprise Value/Revenue
6.39
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-166.91%
Return on Assets (ttm)
-22.63%
Return on Equity (ttm)
-54.05%
Revenue (ttm)
2.33M
Net Income Avi to Common (ttm)
-3.89M
Diluted EPS (ttm)
-0.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
1.33M
Total Debt/Equity (mrq)
26.17%
Levered Free Cash Flow (ttm)
-3.96M